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King’s College London School of Medicine at King’s College Hospital, London, UKAutoimmune hepatitis was one of the ﬁrst liver diseases for Epidemiology
which an effective treatment was developed and the beneﬁt pro-
ven by randomized controlled trials. Nonetheless, both the diag-
nosis and the treatment of autoimmune hepatitis remain full of
challenges. The clinical spectrum is very wide, ranging from sub-
clinical non-progressive disease to fulminant hepatic failure.
Diagnostic criteria based on elevation of IgG, demonstration of
characteristic autoantibodies, and histological features of hepati-
tis in the absence of viral disease are very helpful. However, in
some patients, diagnosis remains a clinical challenge. Adequately
dosed steroids are the mainstay of remission induction treat-
ment, while remission maintenance is best achieved by azathio-
prine. Therapeutic alternatives are required in a small group of
patients responding insufﬁciently to these drugs or intolerant
to their side effects.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Autoimmune hepatitis (AIH) was described as a disease often
severely affecting young women well before viral hepatitis mark-
ers could reliably distinguish viral from non-viral liver disease
[1–3]. The serological demonstration of anti-nuclear antibodies
(ANA) and antibodies to double-stranded DNA (dsDNA) lead to
the term ‘‘lupoid hepatitis’’ [4,5]. A good response to steroids
was observed early on and saved the lives of patients as soon
as the disease was recognized as an autoimmune condition [6].
Three landmark clinical controlled trials in the 70s established
the life-saving value of corticosteroids in the treatment of
patients with ‘‘HBsAg-negative hepatitis’’ [7–11]. In addition, to
establishing the value of immunosuppression in autoimmune
hepatitis, these were some of the earliest controlled clinical trials,
thus advancing clinical science well beyond hepatology. The
present review will mainly concentrate on clinical issues.Journal of Hepatology 20
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E-mail address: alohse@uke.de (A.W. Lohse).Autoimmune hepatitis occurs in all races and in all geographical
areas [12,13]. As it is a relatively rare disease, there are few reliable
epidemiological data published. The few data available suggest a
prevalence of at least 1:10,000 both in Caucasians and in Japanese
[14,15]. However, the subclinical character of the disease in a con-
siderable proportion of patients makes it likely that the true fre-
quency is considerably higher. Regional and racial differences
have not been studied systematically. Large groups of patients
have been reported from regions as diverse as South America,
Alaska, Scandinavia and Australia. In Asia most reports come from
Japan [15]. AIH was long thought to be very uncommon in China,
but with more reﬁned diagnostic work-up of patients, AIH is
increasingly being reported in that country [16,17].
In textbooks, AIH is described as a disease of young women,
the patient group in which the disease was initially reported. A
female predilection has been conﬁrmed in almost all studies with
a female to male ratio of around 3:1 across the world. The age of
manifestation of AIH varies greatly from as early as the ﬁrst year
of life up until the eighties [13,18,19]. As in many other autoim-
mune diseases, both the median and the mean age of initial dis-
ease presentation are in the forties. In children, the mean age of
onset for AIH type 1 is between 10 and 11 years of age and for
AIH type 2 is between 6 and 7 years of age. The universal occur-
rence of AIH, the very wide age range of primary disease manifes-
tation and the involvement of both sexes means that
autoimmune hepatitis needs to be considered in the differential
diagnosis of any patient with laboratory evidence of liver disease.Clinical presentation
The clinical manifestations of autoimmune hepatitis are varied
[12,13]. About a thirdof thepatients come toclinical attentionwith
an acute icteric hepatitis, occasionally evenwith fulminant hepatic
failure [20–22]. The majority of patients have milder and some
even subclinical disease. They may come to clinical attention
because of non-speciﬁc symptoms such as generalized fatigue. In
addition, many patients experience arthralgias without arthritis
and this may lead to a systematic work-up. Increasingly AIH is
diagnosed in patients who show elevated liver function tests on
routine medical tests. At least a third of patients have already cir-
rhosis at presentation, indicating that the disease has gone unrec-
ognized for a considerable period of timeprior to diagnosis. Even in11 vol. 55 j 171–182
Table 1. Extrahepatic disorders associated with autoimmune hepatitis. List of
autoimmune or immune mediated diseases that have been described in patients
with autoimmune hepatitis [22–32]. The strongest association is found with
thyroiditis.
Thyroiditis (Hashimoto)
Vitiligo 
Ulcerative colitis 
Celiac disease 
Type 1 diabetes mellitus 
Systemic lupus erythematosus 
Rheumatoid arthritis 
Mixed connective tissue disease 
Hyperthyroidism (Graves´ disease) 
Panniculitis 
Sjögren´s syndrome 
Mononeuritis 
Urticaria pigmentosa 
Sweet´s syndrome 
Glomerulonephritis
Polyglandular autoimmune syndrome, type I 
Idiopathic thrombocytopenic purpura 
Hemolytic anemia 
Polymyositis 
Uveitis 
Review
the group of patients presenting with acute disease, liver biopsy
often shows signs of advanced ﬁbrosis or cirrhosis.
Acute icteric hepatitis is more common in children and young
adults, and it is particularly in this age group that fulminant
hepatic failure may develop [13]. Nonetheless, even patients in
their seventies can present with fulminant hepatitis and subacute
liver failure, and in these rapid diagnosis and treatment is critical.
A high index of suspicion is important.
A characteristic feature in some patients is an acute relapsing
course. Untreated acute autoimmune hepatitis does not inevita-
bly lead to immediate liver failure, but the majority of patients,
if not diagnosed or for other reasons not treated, will experience
a spontaneous partial recovery, sometimes even a complete nor-
malization of liver function tests. However, histological disease
activity usually persists and another acute exacerbation is usually
experienced within a few months. Others progress to a chronic
hepatitis, mostly with a ﬂuctuating course. Patients with acute
autoimmune hepatitis or an acute ﬂare are almost invariably
icteric with a pronounced degree of jaundice. Most of these
patients also report general symptoms such as malaise, fatigue,
loss of appetite and, as mentioned above, arthralgias. For many
patients, this latter symptom is a parameter of disease activity,
which can be helpful in the clinical management. In patients with
biochemical remission, persistence of arthralgia usually suggests
persistence of inﬂammatory activity in the liver, as can be dem-
onstrated by liver biopsy.
On clinical examination signs of chronic liver disease may be
detectable. Palmar erythema is present not only in association
with cirrhosis. In some patients it may disappear with successful
immunosuppressive therapy. The liver may be palpable as
enlarged, and sometimes swollen and tender. In advanced dis-
ease, nodularity may be palpable.
As autoimmune hepatitis has a genetic predisposition, and
like other autoimmune diseases is associated with a variety of
autoimmune conditions [23–32], both family and personal his-
tory should be taken carefully. Table 1 lists the conditions most
frequently described in association with autoimmune hepatitis.
Like in most autoimmune disorders, the manifestation of differ-
ent autoimmune diseases in the same patient is usually sequen-
tial and only rarely simultaneous.
A number of patients with AIH presents late with cirrhosis, at
times decompensated. Many of them are diagnosed as having
‘‘cryptogenic cirrhosis’’ and in the past AIH was the most com-
mon cause of cryptogenic cirrhosis. Earlier diagnosis and treat-
ment of AIH patients on the one hand and an increasing
number of patients with non-alcoholic steatohepatitis (NASH)
have made the latter diagnosis the most common cause of cryp-
togenic cirrhosis, but AIH remains second.Pathogenesis
Autoimmune hepatitis carries all features of an autoimmune dis-
ease: genetic predisposition, association with other autoimmune
diseases, spontaneous disease ﬂuctuations, autoantibodies, and
auto-reactive T-cells, inﬂammatory inﬁltrate, and a good
response to immunosuppression. As in other autoimmune dis-
eases, the etiology is not understood, nor the factors that may
trigger a ﬂare, and those that may lead to spontaneous remissions
in some patients.172 Journal of Hepatology 201The genetic predisposition is demonstrated best by the HLA-
association of the disease. Different HLA-subtypes contribute dif-
ferent relative risks in different ethnic groups. In Caucasians the
extended HLA haplotypes DRB1⁄0301 and DRB1⁄0401 are
strongly associated with the disease and found in more than half
of the patients, while the haplotype DRB1⁄1501 appears to be
protective [33–36]. In Japan the DRB1⁄0405 haplotype is the
dominant association, while in South America children with
AIH show an association with DRB1⁄1301 and less so with
DRB1⁄0301 and adults with DRB1⁄0405 [34,37], like in Japan
[34,38]. The strength of the HLA-associations and the frequent
association with DRB1⁄ alleles with some common features
across the world suggest that peptide binding to the antigen-pre-
senting parts of the HLA-molecules and presentation of speciﬁc
peptides to HLA-class II restricted CD4+ T-lymphocytes are crucial
to the pathogenesis of autoimmune hepatitis [34,39].
Various other genetic associations have been described in AIH,
but most of these have only been studied in relatively small
groups of patients, and often have not been conﬁrmed by other
studies [34]. These associations have all been with genetic poly-
morphisms of immune response genes that further support the
immunopathogenesis of the disease. This is also corroborated
by the demonstration of autoreactive T-cells and their dysregula-
tion [40–42].
There is strong experimental evidence that under normal cir-
cumstances the liver is an organ of immunological tolerance due
to several regulatory mechanisms including tolerogenic antigen
presentation and secretion of modulatory cytokines such as inter-
leukin 10 and transforming growth factor b [43,44]. Breaking of1 vol. 55 j 171–182
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self-tolerance in the liver may therefore be more difﬁcult than in
other organs [44]. These mechanisms may account for the rela-
tive rarity of autoimmune liver disease and for the observed
spontaneous ﬂuctuation of disease activity. On the other hand,
once tolerance is broken, the presence of pro-inﬂammatory cyto-
kines and activated immune cells may contribute to progression
and perpetuation of damage. A number of animal models of auto-
immune hepatitis have demonstrated that tolerance can be bro-
ken in the liver, albeit not as easily as in some other organs
[45–49]. These models allow testing pathogenic mechanisms
and new therapeutic approaches, though no experimental model
mimics precisely human autoimmune hepatitis as yet.Diagnosis
The heterogeneity of the clinical presentation can make it difﬁ-
cult to diagnose autoimmune hepatitis, and even in very experi-
enced hands the diagnosis at times may remain uncertain.
Diagnosis rests primarily on a high index of suspicion. Autoim-
mune hepatitis should be considered in any patient with elevated
liver enzymes and in any patient with cirrhosis. In 1993 the Inter-
national Autoimmune Hepatitis Group devised a scoring system
to help the standardization of patient populations in scientiﬁc
publications [50]. This scoring system, revised in 1999 [51], has
also been applied by some to daily clinical practice, for which it
had not been primarily designed nor tested, and found to be very
cumbersome. In 2008 the International Autoimmune Hepatitis
Group suggested a simpliﬁed scoring system for clinical practice,
which is useful in most cases [52] (Table 2).
Diagnosis rests on four features: hypergammaglobulinaemia,
autoantibodies, histology and absence of viral hepatitis. Hyper-
gammaglobulinaemia is the cheapest of these screening tests,
the most characteristic ﬁnding being a selective elevation of IgG
with normal levels of IgA and IgM. As the range for normal IgG lev-
els is wide, difﬁculty arises in those AIH patients who physiolog-Table 2. Simpliﬁed diagnostic criteria (2008) of the international autoimmune
hepatitis group [42].
Points
 Autoantibodies  ANA or SMA or LKM >1:40 
ANA or SMA or LKM >1:80 
SLA/LP Positive (>20 units) 
1 
2 
IgG (or gamma-globulius) Upper normal limit 
>1.10 times normal limit 
1 
2 
Liver histology* Compatible with AIH 
Typical for AIH 
1 
2 
Absence of viral hepatitis Yes 
No 
2 
0 
Deﬁnite autoimmune hepatitis (AIH): P7; probable AIH: P6. ANA, antinuclear
antibody; SLA, soluble liver antigen; IgG, immunoglobulin G; AIH, autoimmune
hepatitis.
⁄Typical: (1) Interface hepatitis, lymphocytic/lymphoplasmacytic inﬁltrates in
portal tracts and extending in the lobule; (2) emperipolesis (active penetration by
one cell into and through larger cell); (3) hepatic rosette formation. Compatible:
Chronic hepatitis with lymphoctic inﬁltration without features considered typi-
cal. Atypical: Showing signs of another diagnosis like NAFLD.
Journal of Hepatology 201ically have low baseline levels of IgG. These patients usually have
signiﬁcantly increased IgG levels during phases of disease activity,
but this increase may remain within the normal range. Probably
because of this 5–10% of AIH patients are reported to have normal
IgG levels at diagnosis. Most of these patients have low or even
very low levels after induction of remission. IgG levels are not only
of help in making the diagnosis, but are also very helpful in mon-
itoring disease activity during treatment.
Autoantibodies are a hallmark of autoimmune hepatitis and
constitute an important part of the diagnostic work-up [53,54].
However, there is no simple autoantibody test that can answer
all questions. Anti-nuclear antibodies (ANA) and smooth-muscle
antibodies (SMA) are not disease speciﬁc [53,54]. Antibodies to
liver–kidney microsomes (LKM) are also not disease-speciﬁc,
and, although present in about a third of the children with AIH,
occur in only a small fraction of adult patients [53]. Only SLA/LP-
autoantibodies are disease-speciﬁc, and therefore of high diagnos-
tic value, but can only be detected by commercial assays in upto
30% of AIH patients [55]. For SLA/LP-autoantibodies [56] and
LKM-autoantibodies [57] the molecular identity of the antibody
targets has been identiﬁed and this has allowed the development
of highly speciﬁc immunoassays. Both ANA and SMA are heteroge-
neous and are best detected by immunoﬂuorescence [53] – a diag-
nostic technique coming somewhat out of fashion in large
commercial laboratories in the US, because it is time-consuming
and requires experienced technicians and laboratory physicians.
Nonetheless, the presence of autoantibodies, their titers and their
speciﬁcities are important clues and sometimes the critical com-
ponent in making a diagnosis of autoimmune hepatitis. Immuno-
ﬂuorescence testing on murine tissue sections remains the gold
standard for the detection of ANA and SMA. ANA ﬂuorescence pat-
tern,which in AIH is usually homogeneous, should be further char-
acterized using Hep2 cells [54]. Similarly, testing for anti-actin
may increase sensitivity and speciﬁcity of SMA for AIH [58–60].
Histology is considered a necessary prerequisite for making a
diagnosis of autoimmune hepatitis [43,52]. There are some histo-
logical features that are highly suggestive of the diagnosis, but
like hypergammaglobulinaemia and autoantibodies (except for
SLA/LP probably), histology is not diagnostic in itself [61]. The
revised scoring system distinguishes histology ‘‘compatible with
AIH’’, scoring as 1 point, from histology ‘‘typical for AIH’’, scoring
as 2 points. Compatible with AIH is almost any hepatitic picture
not suggestive of non-alcoholic steatohepatitis (NASH) or drug-
induced inﬂammation. Increasingly, it is important to distinguish
AIH from NASH, and in a few patients both conditions may coex-
ist [62]. ANA and SMA are found, usually at low titers, in up to a
third of patients with NASH [63,64]. Especially in NASH cirrhosis
in elderly women, hypergammaglobulinaemia and autoantibod-
ies can lead to diagnostic confusion, making histological exami-
nation essential for a correct diagnosis [62]. Characteristic
features suggesting typical AIH include interface hepatitis, portal
and periportal inﬂammation, presence of plasma cells, rosetting
of hepatocytes, and emperipolesis (Fig. 1).
Most patients with autoimmune hepatitis have complications
of chronic inﬂammation, including ﬁbrosis, at presentation, and
about a third of them are already cirrhotic. In children, this pro-
portion seems to be even higher [13,65]. Only patients with very
acute presentation may lack features of previous chronic hepati-
tis and ﬁbrosis. Cirrhosis in autoimmune hepatitis is often irreg-
ular and macronodular, and may easily be overlooked by1 vol. 55 j 171–182 173
Fig. 1. Histology of autoimmune hepatitis. Biopsy specimen of a patient with typical features of active autoimmune hepatitis sees as piecemeal necroses, interface
hepatitis, rosette formation and plasma cell enrichment (provided by Dr. A. Quaas, Institute of Pathology, University Medical Centre Hamburg-Eppendorf).
Reviewpercutaneous liver biopsy (Fig. 2). Laparoscopy, a minimally inva-
sive technique with the currently available very small diameter
endoscopes, is helpful in making a diagnosis of cirrhosis in auto-
immune hepatitis, as cirrhosis may be overlooked in up to 40% of
cases without macroscopic assessment of the liver [66–69]. Diag-
nosis of cirrhosis may inﬂuence the choice and dose of the immu-
nosuppressive agents prescribed, has prognostic implications,
and forms the basis for regular screening for complications of cir-
rhosis, such as esophageal varices or hepatocellular carcinoma.
Absence of viral hepatitis was generally thought to be a prere-
quisite for making a diagnosis of autoimmune hepatitis, but in a
few patients viral and autoimmune hepatitis may co-exist. This is
particularly relevant in countries with a high prevalence of viral
hepatitis, where a diagnosis of AIH may be entirely overlooked
in viral hepatitis infected patients. Untreated AIH has usually a
much more severe course and poorer prognosis than chronic viral
hepatitis B or C, and therefore it is important to be able to make a
diagnosis of AIH in such patients. However, both chronic hepatitis
B and hepatitis C virus infection may induce elevation of IgG andFig. 2. Macroscopic aspect of autoimmune cirrhosis. Typical macro modular
cirrhosis of a patient with autoimmune hepatitis diagnosed at a relatively
advanced stage.
174 Journal of Hepatology 201development of autoantibodies. Criteria for AIH in these patients
should therefore be very strict. The revised simpliﬁed scoring sys-
tem allows the diagnosis of AIH in these patients only in the pres-
ence of high IgG levels and high titer autoantibodies as well as a
typical histology, which should be reviewed by an expert liver
histopathologist [52,70]. Long-term follow up of these patients
is required to formulate recommendations.
Two subgroups of patients may be missed by standard diag-
nostic criteria and require special attention: 1. Acute and fulmin-
ant autoimmune hepatitis; 2. Pediatric autoimmune hepatitis.
In acute or fulminant autoimmune hepatitis, hypergamma-
globulinaemia, and autoantibodies may not be present at the time
of clinical presentation.Most of these patients goon todevelop sig-
niﬁcant titers of autoantibodies and high IgG levels, but diagnosis
and institution of immunosuppression need to take place immedi-
ately. In these patients liver biopsy, which is essential for the diag-
nosis of AIH, may be difﬁcult to perform because of severe
coagulopathy and, if performed, may present a further challenge:
in severe acute AIH theremay be centrilobular lesions andnecrosis
mimicking drug-induced liver injury [71,72]. Severe drug-induced
hypersensitivity hepatitis, however, usually responds to high dose
steroids in the same fashion as severe acute autoimmunehepatitis,
and thus the differential diagnosismay be not so relevant if immu-
nosuppression is started without delay [56,73]. The course of the
disease will later allow differentiation between autoimmune and
drug-induced disease: patients with drug-induced hepatitis will
not relapse after withdrawal of immunosuppressive therapy (in
the absence of the offending drug), while autoimmune hepatitis
patients will relapse [73]. In addition, most autoimmune hepatitis
patients showaﬂuctuationof IgG levels in parallel to transaminase
levels and eventually become autoantibody positive.
In pediatric patients it is crucial to use very low cut-off levels
for the deﬁnition of autoantibodies [13,44]. Titers as low as 1:10
for LKM autoantibody and 1:20 for ANA and SMA are pathological
in young children. Cut-off values for SLA/LP have not been evalu-
ated for children.
Despite limitations inherent in any diagnostic score, several
studies have by now conﬁrmed the value of the score, which
appears to serve well in clinical practice [17,70,74–76].1 vol. 55 j 171–182
Table 3. Treatment schedule. Recommended treatment schedule for adult
patients (e.g. 70Kg) with newly diagnosed autoimmune hepatitis. Lower initial
prednisolone doses can be used in cases of mild to moderate disease, or in early
ﬂare-ups after treatment reduction or tapering out of immunosuppressives. Dose
reduction schedules need to be adapted to individual response and side-effect
patterns.
Prednisolone
(mg/d)
Week Azathioprine
(mg/d)
1  70 
( = 1 mg/kg body weight)
2  60  50
3  50  50  
4  40  100*
5  30  100
6  25     100
7  20       100
9+8 15    100
11+01 12.5  100
100from week 12 10      
When transaminases reach normal levels, reduction of prednisolone to 7.5 mg/d,
and after 3 months to 5 mg/d, tapering out at 3 months intervals depending on
individual assessment of risk and response.
⁄Weight adapted dose of 1-1.5 mg/kg body weight.
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Standard treatment
Three randomized trials in the seventies showed unequivocally
the survival beneﬁt of corticosteroid treatment in patients with
what was then called HBsAg-negative chronic active hepatitis
[7–11]. Most patients studied in these trials probably did have
autoimmune hepatitis, but, well over a decade prior to the discov-
ery of the hepatitis C virus, it is conceivable that some of them had
chronic viral hepatitis C. The exclusion of these patients from the
analysis would probably show an evenmore dramatic therapeutic
beneﬁt of steroid treatment. The trials were landmark studies for
both clinical hepatology and for the development of randomized
controlled trials as evidence basis for novel treatments. In addi-
tion, the trials document impressively the dismal prognosis of
untreated symptomatic autoimmune hepatitis, the ﬁve year sur-
vival rate being below 25% in untreated patients versus 80% in
those treated with corticosteroids [11]. While the evidence for
treating symptomatic and jaundiced patientswith AIH is unequiv-
ocal, there is ongoing discussion about the need to treat mild and
asymptomatic disease. We believe that reports of the risk of pro-
gression even in patients with mild disease activity during treat-
ment, and the risk of acute and hyper-acute ﬂares in untreated
patients are strong arguments for treatment of almost all patients
in an individually tailored fashion. In addition, the demonstration
of the presence of the strongly pro-ﬁbrogenic cytokine transform-
ing growth factor b (TGFb) within the liver inﬂammatory inﬁltrate
also in AIH patients with mild disease, stresses the importance of
trying to suppress the tissue inﬂammatory activity even when
laboratory values are normal or near normal [77].
The immunosuppression schedule depends on the severity of
the disease, age and co-morbidities of the patient, and, somewhat
non-scientiﬁcally, on the school of thought of the treating (or rec-
ommending) physicians. The recently published AASLD practice
guidelines recommend either an initial dose of 30 mg prednisone
combined with 1–2 mg of azathioprine per day, or monotherapy
with prednisone at a starting dose of 40–60 mg daily in adults
[78]. For children, a dose of 1–2 mg/kg prednisone up to a daily
dose of 60 mg is recommended in combination with azathioprine
(1–2 mg/kg) or 6-mercaptopurine (1.5 mg/kg). However, as aza-
thioprine is hepatotoxic, particularly in jaundiced patients with
decompensated disease, it is advisable that these patients are trea-
ted with high dose steroids ﬁrst and azathioprine is added later
after partial disease control is achieved and jaundice has subsided.
The adult recommendations are very much based on the doses
used in the Mayo clinic trial of corticosteroid treatment [9] and
can thus be considered evidence based. On the other hand, many
experts have been initiating treatment in adults like in children
with 1 mg/kg body weight of prednisone or prednisolone and
achieved excellent results [13,79,80]. Higher starting doses, we
believe, induce remission more quickly and help to spare steroids
in the long run. A typical treatment schedule is shown in Table 3.
Using this approach we have been able to induce complete remis-
sion, deﬁned as normal transaminase levels, in 91.2% of patients
within six months, and incomplete remission, deﬁned as transam-
inase levels below twice the upper limit of normal, in 98.1% of
patients [79]. As steroid side-effects tend to be few and only tran-
sient, depending on the time period during which a dose of more
than7.5–10 mgperday is used, it seems sensible to reduce steroids
below this dose as quickly as possible. Reduction can be achieved
much faster when higher doses are given at the beginning.Journal of Hepatology 201The debate regarding the correct starting dose of steroids
would ideally be solved by a randomized controlled trial, but it
is unlikely that it will be possible to perform such a study. Careful
case series and analysis of the results in centers using theses dif-
ferent approacheswill therefore need to be undertaken to give fur-
ther guidance. This also applies to the question of the ideal
maintenance therapy. It has long been shown that while steroids
are the drug of choice for induction of remission, azathioprine is
the drug of choice for themaintenance of remission [81]. The opti-
mal dose of azathioprine is also a matter of debate. A careful trial
by the King’s College group demonstrated the effectiveness of
maintenance with azathioprine alone [81], while a second trial
showed that steroid withdrawal is better achieved when azathio-
prine is given at the dose of 2 mg/kg body weight [82]. However,
the tumor rate in this trial was relatively high [83]; because of this,
a maintenance dose of 1–1.5 mg/kg of azathioprine in combina-
tion with low-dose steroids has been recommended in those
patients that fail to reach or maintain complete remission on
low-dose azathioprine monotherapy. The most reasonable
approach is probably to tailor treatment according to the individ-
ual patient depending onwhether the risk of steroid side-effects is
higher than the risk of long-termhigher azathioprine doses, or vice
versa. Fig. 3 shows a treatment algorithm. If the diagnosis of AIH is
not yet deﬁnite, steroids should be given as monotherapy and the
response pattern and relapse rate used as diagnostic test (Fig. 4).
Budesonide is presently receiving considerable attention as an
alternative to prednisone or prednisolone in the treatment of
autoimmune hepatitis. First reports were somewhat contradic-
tory, but a large randomized trial, in fact the largest ever to be
undertaken in AIH, has given encouraging results [84]. In this
Europeanmulticenter trial, treatment starting with 40 mg predni-
sone and weekly dose reduction was compared to 3  3 mg/day
budesonide with reduction only upon response. Remission at1 vol. 55 j 171–182 175
Definite AIH 
Induction Therapya)
Insufficient Response Response 
Increase steroids (i.v.?) Complete Remissionb) Incomplete Remissionc)
Insufficient Response 
Alternative  
Immunosuppressants 
Increase 
Immunosuppression 
Maintenance therapyd)
3-12 months Complete Remission Incomplete Remission 
Liver Biopsye)
Trial of steroid 
withdrawal 
Maintained Remission 
>3 years 
Trial of complete 
treatment withdrawal 
Fig. 3. Management algorithm for patients with deﬁnite autoimmune hepatitis. (a) Induction therapy with initially prednisolone, usually 1 mg/kg/d and azathioprine
1 mg/kg/d according to Table 1. (b) Complete remission is deﬁned as both AST and ALT as well as IgG below the upper limit of normal. (c) Incomplete remission is deﬁned as
improvement of AST/ALT within 2 the upper limit of normal, or normalization of AST and ALT without complete normalization of IgG. (d) Maintenance therapy usually
with 1–1.5 mg/kg azathioprine and 5–7.5 mg prednisolone therapy. (e) Liver biopsy in patients with incomplete remission should exclude alternate diagnoses (such as
azathioprine hepatotoxicity), and should assess the inﬂammatory activity (hepatitis activity index HAI): HAI scores of more than 5 suggest progressive disease and should
lead to increased or alternative immunosuppression, while at lower scores reduction of immunosuppressants can be tried according to individual risk variables. (f) Most
experts recommend a liver biopsy prior to a trial of treatment withdrawal. Treatment withdrawal should not be tried, if there remains signiﬁcant histological disease
activity. In patients with intermittent relapses, treatment should also be maintained long-term.
Review6 months was achieved in 60% of the budesonide group, but in
only 38.8% of the prednisone group [84]. Remission induction thus
was clearly below that reported in series starting with higher
doses of prednisolone. Nonetheless, this trial seems to suggest,
that budesonide can be an alternative in patients in whom steroid
side-effects are expected to be a problem. Importantly, patients
with cirrhosis were excluded from this study, because budesonide
is contraindicated in cirrhosis as the ﬁrst pass effect in the liver is
bypassed in many cirrhotic patients, and complications have been
described [85]. As cirrhosis is present in about a third of patients
at diagnosis, budesonide is not an option for these patients. The
role that budesonide may play in other patients will need to be
deﬁned in the future. In addition, the trial suggests that standard
recommendations of prednisone treatment are suboptimal, as the
dose is too low for many patients.176 Journal of Hepatology 201Management of autoimmune hepatitis requires careful fol-
low-up and strict adherence to treatment by both patients and
treating physicians [86]. Therapy should aim at the complete nor-
malization of transaminase levels. Importantly, IgG levels corre-
late quite closely with histological disease activity, and
normalization of IgG should similarly be aimed for [87]. When
both transaminase and IgG levels are normal, the histological dis-
ease activity is at most mild to minimal, while if either IgG or
transaminase levels are abnormal, about 50% of patients still have
signiﬁcant inﬂammatory activity on biopsy, deﬁned as a histolog-
ical activity index (HAI) score of 6 or more [87]. Follow-up biop-
sies may be particularly helpful in these patients to guide
immunosuppressive therapy (Fig. 3). Alternatively immunosup-
pression can be intensiﬁed in these patients, if well tolerated,
and the effect on the biochemical disease parameters measured.1 vol. 55 j 171–182
Propable or possible 
AIH
Response
(= AIH likely) 
1 mg/kg prednisolone 
Non-response 
Taper steroids 
Consider alternative 
diagnoses 
Relapse Remission 
Definite AIH Withdraw steroids and observe closely >1year 
No relapse 
AIH unlikely 
Fig. 4. Management algorithm for patients with suspected autoimmune hepatitis. A good response to treatment supports the diagnoses, relapse upon dose reduction is
further strong evidence.
JOURNAL OF HEPATOLOGYFollow-up biopsies are also generally recommended before
considering cessation of therapy [88]. Cessation of therapy will
be considered in all patients, and is a question patients will
repeatedly ask. However, many, if not most, patients require
life-long therapy. This certainly applies to all those who continue
to have inﬂammatory activity despite adequately dosed immuno-
suppression. During the reduction of immunosuppression, espe-
cially following steroid withdrawal, about half of the patients
experience a ﬂare, demonstrating the necessity of longer term
therapy [79]. In patients in stable remission on azathioprine
monotherapy, a trial of treatment withdrawal can be undertaken.
The chance of a successful drug withdrawal depends on the
length of treatment and stable remission. A minimum of three
years of treatment appears to be best [88]. Some authors recom-
mend biopsy prior to withdrawal, and do not attempt withdrawal
in patients with continued histological activity. This approach,
however, may not suit all patients. For some it may be justiﬁed
to carefully withdraw therapy in a stepwise fashion with closeJournal of Hepatology 201(monthly) laboratory follow-up. If reactivation of disease is rec-
ognized early and treatment reinstituted quickly, than lower
doses of steroids (usually 0.5 mg/kg) will sufﬁce, and remission
is usually reached rapidly. Even patients in stable remission off
therapy should be followed up regularly, because reemergence
of the disease can occur any time, even decades after stable
remission.
Prognosis of treated autoimmune hepatitis is good [79]. Some
centers report normal life expectancy rates, but there may be a
patient selection bias. In particular some patients with early
severe disease progress rapidly despite immunosuppression and
require liver transplantation. Moreover, patients presenting with
already advanced cirrhosis or liver failure may die in the early
phase of treatment because of infectious complications related
to immunosuppression. The experience of the attending physi-
cian is also likely to inﬂuence the prognosis, but there are no pub-
lished data on this effect. Finally, patient’s adherence to
treatment is of paramount importance.1 vol. 55 j 171–182 177
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Pregnancy
Autoimmune hepatitis affects mainly young females, raising the
question of pregnancy in this disease. Several centers have col-
lected their data and tried to come to some recommendations on
the basis of these observations [89–91]. Even though these types
of studies inevitably leave a considerable amount of uncertainty
due to the limited number of patients and their observational
character, the message is encouragingly uniform: pregnancy in
AIH is generally safe for both mother and child. There seems to
be a somewhat higher rate of (mostly early) miscarriage, but this
seems to be unrelated to the treatment being given [89–91]. Aza-
thioprine, even though being a class D drug of uncertain safely in
pregnancy, was not related to miscarriage or other pregnancy
complications. AIH activity is often observed to be milder during
pregnancy, as has also been described for other autoimmune dis-
eases, and this may allow tapering of immunosuppression espe-
cially during the early stages. However, occasional ﬂares up to
fulminant liver failure can occur during pregnancy, therefore
immunosuppression should be upheld at a reasonable level that
has been individually assessed for each patient.
In addition, post-partum ﬂares of the disease are frequent, and
we recommend increasing the steroid dose shortly before the
expected date of delivery, and to monitor liver enzymes and
IgG levels closely in the weeks following delivery.Difﬁcult to treat patients
Most, but not all patients respond very well to treatment. Non-
response, intolerance of the drug or drug side-effects may lead
to management problems in AIH. Furthermore, patients with
AIH and features of sclerosing cholangitis or primary biliary cir-
rhosis (overlap syndromes) may present a therapeutic challenge.
Finally, co-morbidities may limit therapeutic options and thus
inﬂuence management of autoimmune hepatitis.
Non-response
Response to immunosuppression in AIH is so universal that it is
considered to be a diagnostic criterion. Thus, non-response
should question the diagnosis, and perhaps adherence to treat-
ment (Fig. 4). Nonetheless, a few patients show an insufﬁcient
response to standard immunosuppression, and some show reacti-
vation during reduction of steroid doses at levels higher than can
be tolerated. Therapeutic management of these cases can be chal-
lenging. Due to the relative rarity of this situation, only a few case
series have been published that can guide treatment. Initially,
intravenous prednisolone at doses of 100 mg daily or more may
be required in a few aggressive cases with severe jaundice, as
these may also suffer from malabsorption. In patients intolerant
to azathioprine, mycophenolate mofetil seems to be a relatively
good alternative [92–94]. It appears to be of very limited efﬁcacy
in patients with an insufﬁcient response to azathioprine [95], but
experience in children is more favorable than in adults [96]. In
these patients stronger immunosuppressive agents appear to be
required, and good results have been reported with cyclophos-
phamide [97], methotrexate [98], cyclosporine [99], tacrolimus
[94,100] and inﬂiximab [101]. No comparative data are available.
The decision should thus be based on local and personal expertise.178 Journal of Hepatology 201It appears that the calcineurin inhibitors cyclosporine and tacrol-
imus are efﬁcient agents, but like in other autoimmune diseases
they are not immunomodulatory, and therefore tend to require
permanent treatment, while immunomodulatory agents such as
cyclophosphamide or inﬂiximabmay allow reduction of immuno-
suppression over time. Speciﬁc studies on second line treatment
for difﬁcult to treat patients are needed.Non-compliance
Compliance is rarely a problem in acute disease, but can be a prob-
lem during follow-up. A particularly difﬁcult to manage group are
pediatric patients entering puberty [13]. Non adherence to treat-
ment is particularly frequent in adolescents, who do not accept
treatment side effects and deny their disease in an attempt to
be ‘normal’, with consequent high relapse rate, at times leading
to liver failure [86]. Like in other chronic diseases, during puberty
management requires careful motivation of the patients and their
parents, which is better achieved in specialized transition services
with a multidisciplinary approach, including pediatric and adult
hepatologists, psychologists and nurse specialists.Drug intolerance
Intolerance to azathioprine occurs in 3–5% of patients and is of an
idiosyncratic nature [79]. Intolerance manifests itself within a
few weeks, and mostly during the very ﬁrst days of treatment.
It is important to recognize intolerance and stop the drug imme-
diately, which usually results in the resolution of symptoms
within a couple of days. If in doubt, re-exposure should be
attempted with a low dose, which in case of true intolerance will
lead to rapid reemergence of symptoms. In patients intolerant to
azathioprine, mycophenolate mofetil appears to be a good alter-
native with a long-term response rate around 70% and should be
the ﬁrst choice drug in patients intolerant to azathioprine. Other
alternatives are steroid monotherapy in patients with mild
disease and little steroid risk factors, or any of the immunosup-
pressives used also in non-responders, i.e. methotrexate, cyclo-
phosphamide, calcineurin inhibitors or inﬂiximab.Overlap syndromes
Patients with clinical, laboratory, and histological features of both
autoimmune hepatitis and one of the cholestatic liver diseases
primary biliary cirrhosis (PBC) or primary sclerosing cholangitis
(PSC) have often been labeled as suffering from overlap syn-
dromes [102]. This term is probably misleading as very rarely
there is a true overlap of the two conditions, but most patients
suffer from active or aggressive forms of PBC [103] or PSC
[104]. In children particularly, however, this secondary aggres-
sive hepatitic picture can be so dominant that patients mostly
manifest initially as typical autoimmune hepatitis [105]. This
has lead to the term autoimmune sclerosing cholangitis for these
children [105]. The parenchymal liver disease in autoimmune
sclerosing cholangitis responds satisfactorily to the same immu-
nosuppression schedule used for AIH, with the addition of med-
ium dose ursodeoxycholic acid (15 mg/kg/day), though in some
50% of patients the bile duct disease progresses [105]. At the
other end of the spectrum, about 10–20% of adult patients with1 vol. 55 j 171–182
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PBC have an insufﬁcient response to treatment with ursodeoxy-
cholic acid and have been shown to beneﬁt from usually low dose
prednisolone therapy [106]. It remains controversial to what
extent these patients should be considered as suffering from
autoimmune hepatitis [102]. Nonetheless, since the very poor
prognosis of untreated autoimmune hepatitis and the excellent
response to immunosuppression seem to apply similarly to these
patients with secondary autoimmune hepatitis, immunosuppres-
sive treatment should be guided by the same principles as in
straightforward autoimmune hepatitis [103,106]. In hepatitic
forms of PBC (in the past PBC/AIH overlap) it is usually sufﬁcient
to treat with doses of steroids lower than in classical autoimmune
hepatitis, and many patients can be kept very successfully on low
dose azathioprine in the long term, not requiring corticosteroids.
In hepatitic forms of PSC (autoimmune sclerosing cholangitis and/
or AIH/PSC overlap) immunosuppression is often required in the
same fashion as in AIH, but response tends to be incomplete,
and the disease progresses, albeit more slowly, despite immuno-
suppressive therapy, resulting in the eventual need for liver trans-
plantation in the majority of affected patients [107].Hepatocellular carcinoma
It was long thought that in autoimmune liver diseases the risk of
hepatocellular carcinoma (HCC) is negligible. However, recent
reports of HCC in both PBC and AIH have highlighted that this pre-
sumption can no longer be upheld [108–110]. The relative rarity
of AIH makes it impossible to evaluate reliably the incidence of
HCC in AIH cirrhosis, but as several cases of HCC in AIH cirrhosis
have been reported from a variety of centers, it appears reason-
able to include AIH cirrhosis among the conditions justifying reg-
ular ultrasound screening for the development of neoplastic foci.
Ultrasound evaluation can be difﬁcult as AIH is associated with
macronodular cirrhosis, thus making it hard to distinguish regen-
erative nodules from neoplastic nodules. Patterns on contrast
ultrasound and other imaging techniques can help, but occasion-
ally biopsy may be required. In view of the need of regular ultra-
sound examinations of cirrhotic patients with AIH, it is important
to make a diagnosis of cirrhosis in a timely fashion.Role of liver transplantation
Liver transplantation is only rarely required for patients with
autoimmune hepatitis, but is more common in children, who
present more often with fulminant hepatitis, than in adults. Main
reasons for transplantation are fulminant disease not responding
to steroids quickly enough, progression due to (intermittent)
non-compliance, and long-term progression despite adequate
treatment in initially already advanced cirrhosis.
In fulminant disease steroids need to be given as early as pos-
sible, usually before the diagnosis is ﬁnally conﬁrmed, in order to
give the patient a chance of recovery. We would recommend
100 mg i.v. daily for these patients. Unless there is a clear-cut
response within the ﬁrst 14 days, it is probably better to proceed
with transplantation in eligible patients than to hope longer for a
good response [111]. Prolonged high-dose immunosuppression
in a patient with liver failure leads to a very high risk of infectious
complications, which may endanger the results of emergencyJournal of Hepatology 201transplantation. Antibiotic prophylaxis during high-dose immu-
nosuppression in these patients is recommended.
In children presenting with acute liver failure (INR >2) and
encephalopathy grade II–IV, transplantation is usually the only
therapeutic option. For those children with acute liver failure
without encephalopathy, prednisolone at the dose of 2 mg/kg/
day, rapidly decreased according to biochemical response over
6–8 weeks to a dose of 5–10 mg daily, is usually effective in
achieving remission.
In patients deteriorating because of non-adherence, the deci-
sion to proceed to transplantation can be most challenging, as
strict adherence to treatment is essential for the success of liver
transplantation. As this question arises mostly in adolescents
and young adults, most centers would give the patient one
chance with a new liver, but close follow up with strong psycho-
logical input is essential post surgery.
Patients with advanced cirrhosis at initial presentation may
progress to end stage liver disease despite adequate immunosup-
pression and adherence to treatment. In these, transplantation is
a good option, with altogether good results. Manipulation of
immunosuppression to achieve both rejection prevention and
prevention of AIH recurrence needs to be considered.
The risk of recurrence of AIH seems to be particularly high in
those patients transplanted when the disease is active, and there-
fore post-transplant treatment should aim both at suppression of
rejection and suppression of AIH [112]. In these patients low dose
steroids (5 mg daily) should be continued indeﬁnitely and azathi-
oprine, a drug out of fashion in the liver transplant community,
should be combined with standard calcineurin inhibitors. MMF
can be used as an alternative.
Recurrent AIH, reported in some 20% of cases [113], may occur
even years after grafting and is diagnosed on the basis of bio-
chemical abnormalities, presence of autoantibodies, interface
hepatitis on liver histology and/or steroid dependence. Addition-
ally, a form of graft dysfunction called de novo AIH, associated
with positive autoantibodies, high IgG, histological features of
interface hepatitis has been described in 6–10% of patients trans-
planted for non autoimmune disorders [114]. This condition does
not respond satisfactorily to anti-rejection regimens, but only to
the standard treatment for AIH [114], or, in resistant cases, to
rapamycin [115].
The European transplant registry shows that the results in AIH
overall are fairly good, but not as good as they are in PBC, infec-
tious complications being a frequent reason for an untoward out-
come [116].Future outlook
After many decades of research into autoimmune hepatitis, like in
other autoimmune diseases, we still do not knowwhat causes the
disease process. Identifying cause and trigger of the inﬂammatory
process would not only greatly advance our understanding, but
help in the design of more speciﬁc and more effective immune
interventions. Animal models provide clues, and the complexity
of immune regulation in the liver is beginning to become unrav-
eled [43]. At the same time, advances in the immunotherapy of
other more common and more severe autoimmune diseases, such
as multiple sclerosis or rheumatoid arthritis, need to be trans-
ferred to autoimmune hepatitis. Specialized centers across the1 vol. 55 j 171–182 179
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world should collaborate in clinical trials, particularly in regard to
difﬁcult-to-treat patients. At the same time, we need to increase
the awareness that autoimmune hepatitis should be considered
in the differential diagnosis of any elevation of liver enzymes,
and that it is important to adapt immunosuppressive therapy to
the individual needs of our patients. The great advances of the past
should beneﬁt the many patients as yet undiagnosed or under-
treated. In addition to the scientiﬁc challenge of understanding
the cause of this enigmatic disease, the biggest challenge is educa-
tional: to recognize and diagnose AIH, and treat it skillfully.
Key Points 1  
Autoimmune Hepatitis (AIH) can affect patients of all 
age groups 
The peak age at first manifestation is between 40 and 
50, but manifestations in young childhood are also 
common 
AIH is more common in women (female : male ratio 3 : 1). 
Children and younger adults often have an acute 
disease onset 
Subclinical and asymptomatic disease is common, 
AIH therefore needs to be considered in the differential 
diagnosis of all patients with elevated liver enzymesKey Points 2  
Diagnosis is based on four major criteria: 
)snilubolgammaglatotro(slevelGgIdetavele
seidobitnaotuacitsiretcarahc
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sititapehlarivfoecnesba
Response to immunosuppression is characteristic and 
supports the diagnosis Key Points 3 
Corticosteroids are the drug of choice for remission 
induction in AIH 
Higher starting doses allow more rapid steroid tapering 
and result in faster remission  
Remission is defined by normal transaminase and IgG 
levels, or by histology showing no more than minimal 
inflammatory activity; this should always be the 
therapeutic aim 
Azathioprine is the drug of choice for maintenance of 
remission. 
In patients intolerant to azathioprine, other 
imunosuppressants, preferably mycophenolate mofetil, 
should be tried 
Failure to reach stable remission should question the 
diagnosis 
After reaching remission, steroids might be cautiously 
tapered out 
Maintenance immunosuppression (usually 
azathioprine) should be given for a minimum of three 
years   180 Journal of Hepatology 201Conﬂict of interest
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